We need to test all the variations. Shorter or longer lasting compounds could be better, and for different purposes. And work may move into the direction of tailoring duration, like the older work that Gouzoulis-Mayfrank did with continuously infused intravenous DMT, in which the duration and intensity can be adjusted. There may be compounds that have less chance of a particularly difficult experience. It is another question whether this would improve treatment. It would certainly make it more attractive to a broader array of patients. Shulgin was particularly interested in 4-OH-DIPT as a therapeutic, as a somewhat shorter acting psilocybin-like compound. Lots to explore!
We need to test all the variations. Shorter or longer lasting compounds could be better, and for different purposes. And work may move into the direction of tailoring duration, like the older work that Gouzoulis-Mayfrank did with continuously infused intravenous DMT, in which the duration and intensity can be adjusted. There may be compounds that have less chance of a particularly difficult experience. It is another question whether this would improve treatment. It would certainly make it more attractive to a broader array of patients. Shulgin was particularly interested in 4-OH-DIPT as a therapeutic, as a somewhat shorter acting psilocybin-like compound. Lots to explore!